Previous functional assays revealed that adrenomedullin enhances MM-driven neo-angiogenesis implying that CGRPR inhibitors represent a drug class that could potentially reverse MM’s angiogenic switch (52). The gene discussed is CALCRL; the disease is Miyoshi myopathy.